Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Sachio Aoyanagi"'
Autor:
Nobuaki Minami, Shigeru Nakajima, Sachio Aoyanagi, Atsuko Mokubo, Masashi Ishikawa, Masahiro Takihata, Yasushi Tanaka, Takehiro Kawata, Kotaro Iemitsu, Takashi Iizuka, Ikuro Matsuba, Akira Kanamori, Akira Kubota, Kazuaki Shinoda, Taisuke Kikuchi, Mizuki Kaneshiro, Tatsuya Saito, Kazuhiko Hoshino, Keiji Tanaka, Nobuo Sasai, Mitsuo Obana, Masahiko Takai, Hikaru Amemiya, Hideaki Kaneshige, Yoko Matsuzawa, Hiroshi Takeda, Hideo Machimura, Yasuo Terauchi, Taro Asakura, Fuyuki Minagawa, Shinichi Umezawa, Tetsuo Takuma, Masaaki Miyakawa, Shogo Ito
Publikováno v:
Journal of Clinical Medicine Research
Background: Ipragliflozin is a selective sodium glucose co-transporter 2 inhibitor. The ASSIGN-K study is investigating the efficacy and safety of ipragliflozin for type 2 diabetes mellitus (T2DM) in the real-world clinical setting. Methods: Japanese
Autor:
Yasushi Tanaka, Ikuro Matsuba, Atsuko Mokubo, Sachio Aoyanagi, Yasuo Terauchi, Hikaru Amemiya, Hiroshi Takeda, Akira Kanamori, Nobuaki Minami, Akira Kubota, Hideaki Kaneshige, Shigeru Nakajima, Yoko Matsuzawa, Hideo Machimura, Kazuaki Shinoda, Takehiro Kawata, Takashi Iizuka, Tatsuya Saito, Mizuki Kaneshiro, Masahiko Takai, Keiji Tanaka, Taro Asakura, Masahiro Takihata, Fuyuki Minagawa, Mitsuo Obana, Masashi Ishikawa, Taisuke Kikuchi, Kazuhiko Hoshino, Kotaro Iemitsu, Nobuo Sasai, Shinichi Umezawa, Shogo Ito, Tetsuo Takuma, Masaaki Miyakawa
Publikováno v:
Journal of Clinical Medicine Research
Background: Ipragliflozin, a sodium-glucose transporter 2 inhibitor, was administered to patients with type 2 diabetes mellitus for 24 weeks to evaluate its effect on glycemic control and body composition. Methods: This was an investigator-initiated